Industrial, Manufacturing & Heavy Industry Market News

Plasma fractionation market worth 29.50 billion USD by 2023 according to new research report

Industrial Market Research

The plasma fractionation market is expected to reach USD 29.50 Billion by 2023 from an estimated USD 21.23 Billion in 2018, at a CAGR of 6.8%. The key factors driving the growth of this market include the growing geriatric population across the globe, growing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency (AATD) driving the uptake of alpha-1-antitrypsin, and increase in plasma collection.

- Advertising -

Browse 197 market data Tables and 53 Figures spread through 247 Pages and in-depth TOC on "Plasma Fractionation Market - Global Forecast to 2023"
www.marketsandmarkets.com/Market-R…ket-93798284.html

By product, the immunoglobulins segment accounted for the largest share of the market in 2017

On the basis of product, the plasma fractionation market is broadly segmented into immunoglobulins, coagulation factors, albumin, protease inhibitors, and other plasma products. In 2017, the immunoglobulins segment accounted for the largest share of this market.

The large share of this segment can be attributed to the higher adoption of immunoglobulins in various neurological and immunological diseases, increasing use of on and off-label immunoglobulin for various indications, and rising adoption of subcutaneous immunoglobulins.

- Advertising -

However, the protease inhibitors segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is primarily attributed to the increased prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

By application, neurology accounted for the largest share of this market in 2017

On the basis of applications, the plasma fractionation market is further segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2017, the neurology segment held the largest share of this market.

This can primarily be attributed to the increasing use of IVIG in the treatment of various neurological diseases, better response of IVIG in a shorter period than steroids or oral immunosuppressants, and its effectiveness in a number of disorders of peripheral and central nervous systems.

Report: www.marketsandmarkets.com/requests…e.asp?id=93798284

Hospitals and clinics were the largest end users of plasma fractionation products in 2017

Based on end users, this market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. In 2017, the hospitals & clinics segment held the largest share of this market and is expected to grow at the highest CAGR during the forecast period due to the increasing adoption of plasma products in the treatment of various diseases, large patient pool treated in hospitals, and increasing number of hospitals & clinics across the globe.

North America dominated the market in 2017

North America accounted for the largest share of the plasma fractionation market in 2017, followed by Europe and Asia Pacific. North America’s prominence in this market is mainly attributed to the increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for diagnosed patients.

In addition, the rising number of registered hemophilic patients is also propelling the growth of this market.

The key players in the global plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

 

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany profile: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...